UNSPSC 51361912: Cyclobarbital or cyclobarbitol or cyclobarbiton

This classification denotes a sedative and hypnotic with the molecular formula C12H16N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0M8A98AD9H, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(1-cyclohexen-1-yl)-5-ethyl- but generally known as cyclobarbital, which bears US NIH Compound Identifier 5838. European Medicines Agency schedules Cyclobarbital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06848MIG. The term CYCLOBARBITAL is an International Non-Proprietary Name.

World Health Organization schedules cyclobarbital in its Anatomical Therapeutic Chemical (ATC) Classification. CYCLOBARBITAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CCC1(C(=O)NC(=O)NC1=O)C2=CCCCC2.

UNSPSC 51361912 Cyclobarbital or cyclobarbitol or cyclobarbiton is a Commodity code that nominally covers a specific controlled barbiturate pharmaceutical, but recent state and local procurement activity under this code shows little alignment with the code's actual scope. The recent opportunities posted under the code involve naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer prescription programs (Texas Health and Human Services Commission), and generic multi-source pharmaceuticals and over-the-counter products (Minnesota Multistate Cooperative Purchasing Alliance). None of these solicitations target cyclobarbital or related barbiturates specifically, suggesting either broad miscoding of pharmaceutical procurement activity under a narrow commodity designation or tag drift in the sourcing databases. State and local issuers tagging opportunities this way include county health departments, state health and human services agencies, and multi-state cooperative purchasing organizations.

The three recent opportunities span Florida, Texas, and Minnesota, representing distinct procurement models and product categories. Seminole County's IFB60459723LAS (posted June 30, 2026; due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building. The Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) gathered vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota MMCAP's RFP S1070000015802 (posted January 20, 2026; due March 26, 2026) established multiple-award contracts for generic pharmaceuticals and OTC products across participating state and local facilities, with awards effective July 1, 2026 and contract terms through June 30, 2028. The code's actual recent activity does not support targeted pursuit under the cyclobarbital designation; vendors interested in state and local pharmaceutical procurement should monitor broader pharmaceutical class codes and cooperative purchasing vehicles rather than rely on this commodity-level tag.